• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

重度胰岛素抵抗患者的治疗方法

Treatment Approach to Patients With Severe Insulin Resistance.

作者信息

Church Timothy J, Haines Stuart T

机构信息

West Palm Beach Veteran's Administration Medical Center, West Palm Beach, FL.

University of Maryland School of Pharmacy, Department of Pharmacy Practice and Science, Baltimore, MD.

出版信息

Clin Diabetes. 2016 Apr;34(2):97-104. doi: 10.2337/diaclin.34.2.97.

DOI:10.2337/diaclin.34.2.97
PMID:27092020
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4833480/
Abstract

In Brief Patients with severe insulin resistance require >2 units/kg of body weight or 200 units/day of insulin. Yet, many patients do not achieve glycemic targets despite using very high doses of insulin. Insulin can cause weight gain, which further contributes to worsening insulin resistance. This article describes the pharmacological options for managing patients with severe insulin resistance, including the use of U-500 insulin and newer agents in combination with insulin.

摘要

简而言之，严重胰岛素抵抗患者所需胰岛素剂量>2单位/千克体重或200单位/天。然而，许多患者尽管使用了非常高剂量的胰岛素，仍未达到血糖目标。胰岛素会导致体重增加，这进一步加重胰岛素抵抗。本文介绍了治疗严重胰岛素抵抗患者的药物选择，包括使用U-500胰岛素和新型药物联合胰岛素治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a509/4833480/6e3968fd02c8/97fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a509/4833480/6e3968fd02c8/97fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a509/4833480/6e3968fd02c8/97fig1.jpg

相似文献

1
Treatment Approach to Patients With Severe Insulin Resistance.重度胰岛素抵抗患者的治疗方法
Clin Diabetes. 2016 Apr;34(2):97-104. doi: 10.2337/diaclin.34.2.97.
2
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.管理高度胰岛素抵抗型糖尿病：减肥方法和医学管理。
Postgrad Med. 2010 Jan;122(1):163-71. doi: 10.3810/pgm.2010.01.2110.
3
Managing type 2 diabetes: going beyond glycemic control.管理2型糖尿病：超越血糖控制
J Manag Care Pharm. 2008 Jun;14(5 Suppl B):s2-19.
4
Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus.
J Clin Endocrinol Metab. 1997 Dec;82(12):4037-43. doi: 10.1210/jcem.82.12.4460.
5
Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.胰岛素甘精 300 单位/毫升个体化靶向治疗在韩国初诊 2 型糖尿病患者中的真实世界结局：TOBE 研究。
Adv Ther. 2024 May;41(5):1967-1982. doi: 10.1007/s12325-024-02830-z. Epub 2024 Mar 21.
6
Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.以生理和体重为中心的 2 型糖尿病治疗策略：二甲双胍、胰高血糖素样肽-1 受体激动剂和胰岛素（MGI）方法。
Postgrad Med. 2013 May;125(3):112-26. doi: 10.3810/pgm.2013.05.2666.
7
Durability of glycemic control using U-500 insulin.U-500 胰岛素控制血糖的持久性。
Diabetes Res Clin Pract. 2012 Mar;95(3):340-4. doi: 10.1016/j.diabres.2011.10.030. Epub 2011 Nov 15.
8
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.胰岛素联合或不联合口服降糖药持续治疗非胰岛素依赖型糖尿病患者继发性失效的比较。
Diabetes Care. 1995 Mar;18(3):307-14. doi: 10.2337/diacare.18.3.307.
9
The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.利拉鲁肽联合 U-500 胰岛素治疗 2 型糖尿病且胰岛素需求较高患者的疗效。
Diabetes Technol Ther. 2011 May;13(5):592-5. doi: 10.1089/dia.2010.0221. Epub 2011 Mar 15.
10
Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.在接近血糖目标的1型糖尿病患者中，联用普兰林肽进行辅助治疗可降低糖化血红蛋白水平，且不会伴随体重增加以及严重低血糖风险升高。
Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):199-204. doi: 10.1055/s-2005-837662.

引用本文的文献

1
Severe Insulin Resistance Syndromes: Clinical Spectrum and Management.严重胰岛素抵抗综合征：临床谱与管理
Int J Mol Sci. 2025 Jun 13;26(12):5669. doi: 10.3390/ijms26125669.
2
Interaction between the gene and dietary intake on metabolic syndrome risk factors among Saudi Arabian adults.沙特阿拉伯成年人中基因与饮食摄入对代谢综合征风险因素的相互作用。
Front Nutr. 2025 Mar 18;12:1513088. doi: 10.3389/fnut.2025.1513088. eCollection 2025.
3
Beyond one size fits all: Probing patient choices in gestational diabetes management, from screening to postpartum.

本文引用的文献

1
GLP-1 receptor agonists: a review of head-to-head clinical studies.GLP-1 受体激动剂：头对头临床研究综述。
Ther Adv Endocrinol Metab. 2015 Feb;6(1):19-28. doi: 10.1177/2042018814559725.
2
Evaluating the effect of u-500 insulin therapy on glycemic control in veterans with type 2 diabetes.评估U-500胰岛素疗法对2型糖尿病退伍军人血糖控制的影响。
Clin Diabetes. 2015 Jan;33(1):14-9. doi: 10.2337/diaclin.33.1.14.
3
Pharmacological management of obesity: an endocrine Society clinical practice guideline.肥胖的药物治疗：内分泌学会临床实践指南
超越“一刀切”：探究妊娠期糖尿病管理中患者从筛查到产后的选择。
Chronic Dis Transl Med. 2024 Oct 25;11(1):33-45. doi: 10.1002/cdt3.153. eCollection 2025 Mar.
4
Insulin Resistance, Hyperinsulinemia and Atherosclerosis: Insights into Pathophysiological Aspects and Future Therapeutic Prospects.胰岛素抵抗、高胰岛素血症与动脉粥样硬化：对病理生理方面及未来治疗前景的见解
Curr Cardiol Rev. 2025;21(1):e1573403X314035. doi: 10.2174/011573403X314035241006185109.
5
Prevalence and predictors of hypoglycemia in older outpatients with type 2 diabetes mellitus.2 型糖尿病老年门诊患者低血糖的患病率及其预测因素。
PLoS One. 2024 Aug 29;19(8):e0309618. doi: 10.1371/journal.pone.0309618. eCollection 2024.
6
Rabson-Mendenhall Syndrome: Analysis of the Clinical Characteristics and Gene Mutations in 42 Patients.拉布森-门登霍尔综合征：42例患者的临床特征与基因突变分析
J Endocr Soc. 2024 Jun 16;8(8):bvae123. doi: 10.1210/jendso/bvae123. eCollection 2024 Jul 1.
7
A Novel Mutation in the Gene Causes Severe Insulin Resistance and Rabson-Mendenhall Syndrome in a Paraguayan Patient.一个新的基因突变导致巴拉圭患者严重胰岛素抵抗和 Rabson-Mendenhall 综合征。
Int J Mol Sci. 2024 Mar 8;25(6):3143. doi: 10.3390/ijms25063143.
8
Factors Associated With Improved A1C Values Among People Using High-Dose Insulin With Uncontrolled Type 2 Diabetes.使用大剂量胰岛素但2型糖尿病控制不佳的人群中与糖化血红蛋白（A1C）值改善相关的因素
Clin Diabetes. 2024 Winter;42(1):87-95. doi: 10.2337/cd23-0006. Epub 2023 Aug 21.
9
Extremely high-dose insulin requirement in a diabetic patient with psychiatric illness: A case report.一名患有精神疾病的糖尿病患者对极高剂量胰岛素的需求：病例报告
SAGE Open Med Case Rep. 2023 Dec 20;11:2050313X231220834. doi: 10.1177/2050313X231220834. eCollection 2023.
10
Molecular Mechanisms for the Vicious Cycle between Insulin Resistance and the Inflammatory Response in Obesity.肥胖症中胰岛素抵抗与炎症反应之间恶性循环的分子机制。
Int J Mol Sci. 2023 Jun 6;24(12):9818. doi: 10.3390/ijms24129818.
J Clin Endocrinol Metab. 2015 Feb;100(2):342-62. doi: 10.1210/jc.2014-3415. Epub 2015 Jan 15.
4
The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病联合治疗中的潜在作用。
Expert Opin Pharmacother. 2014 Dec;15(17):2565-85. doi: 10.1517/14656566.2014.968551. Epub 2014 Oct 15.
5
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.胰高血糖素样肽-1 受体激动剂与基础胰岛素联合治疗 2 型糖尿病的系统评价和荟萃分析。
Lancet. 2014 Dec 20;384(9961):2228-34. doi: 10.1016/S0140-6736(14)61335-0. Epub 2014 Sep 11.
6
A 24-week, prospective, randomized, open-label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance to assess the addition of exenatide on the efficacy of u-500 regular insulin plus metformin.一项为期24周的前瞻性、随机、开放标签、达标治疗的试点研究，对象为患有严重胰岛素抵抗的肥胖2型糖尿病患者，旨在评估添加艾塞那肽对u-500常规胰岛素联合二甲双胍疗效的影响。
Endocr Pract. 2014 Nov;20(11):1143-50. doi: 10.4158/EP14067.OR.
7
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.在肥胖且血糖控制不佳的 2 型糖尿病患者中，加用恩格列净可改善血糖控制，减少胰岛素用量，且不增加低血糖风险。
Diabetes Care. 2014 Jul;37(7):1815-23. doi: 10.2337/dc13-3055. Epub 2014 Jun 14.
8
The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.利拉鲁肽联合大剂量胰岛素强化治疗的效果：一项随机前瞻性试验。
Diabetes Obes Metab. 2014 Sep;16(9):827-32. doi: 10.1111/dom.12286. Epub 2014 Mar 25.
9
Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update.摘自《美国老年医学会改善老年糖尿病患者护理指南：2013年更新版》的指南摘要。
J Am Geriatr Soc. 2013 Nov;61(11):2020-6. doi: 10.1111/jgs.12514.
10
Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'.对《KDIGO 2012慢性肾脏病评估与管理临床实践指南》的评论
Kidney Int. 2013 Sep;84(3):622-3. doi: 10.1038/ki.2013.243.